With the publication of mailbox patent applications in the Official Gazette, a fierce battle has erupted between Indian and multinational pharmaceutical companies. According to media reports, Indian drug companies including Cipla, Ranbaxy and Cadila have filed around 45 pre-grant oppositions in the form of representations with the Controller of Patents. Major targets include Novartis' anti-asthma molecule, Pfizer's new controlled use of a known molecule and Scherring's formulation for PEG Interferon Alpha conjugates.